Fas Ligand (FasL, Apo-1L/CD95L) Expression and Clinical Outcome in Papillary Microcarcinoma and Papillary Thyroid Carcinomas with Diameter Smaller than 1.5 Centimeters

Bayraktaroglu, T.; Boztepe, H.; Kapran, Y.; Tanakol, R.; Alagoel, F.

doi:10.1055/s-0029-1241205

Fas Ligand (FasL, Apo-1L/CD95L) Expression and Clinical Outcome in Papillary Microcarcinoma and Papillary Thyroid Carcinomas with Diameter Smaller than 1.5 Centimeters

Copy For Citation

Bayraktaroglu T., Boztepe H., Kapran Y., Tanakol R., Alagoel F.

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, vol.118, no.8, pp.537-543, 2010 (SCI-Expanded)

Publication Type: Article / Article
Volume: 118 Issue: 8
Publication Date: 2010
Doi Number: 10.1055/s-0029-1241205
Journal Name: EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.537-543
Istanbul University Affiliated: Yes

Abstract

Context: The presence and the importance of FasL (FasL, APO-1L/CD95L) in papillary microcarcinoma lesions which are smaller than 1.5 cm of the thyroid is unclear.